Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quest Pharmatech Inc V.QPT

Alternate Symbol(s):  QPTFF

Healthcare Biotechnology
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.


TSXV:QPT - Post by User

Quest Pharmatech Inc
Bullboard Posts
User Avatar Image
(106)
•••
Comment by G1945Von Apr 24, 2020 10:21am
118 Views
Post# 30949073

RE:RE:RE:RE:RE:RE:Confusing

RE:RE:RE:RE:RE:RE:ConfusingI just don't see real cash moving into Quest to move Quest's SPP with this deal right now. All this has done is to increase Quest's ownership from 36% to ~ 40%, in OncoQuest. It seems that this deal benefited OncoQuest's shareholders. Therefor nothing changed for Quest other than should Dual be successful with Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer perhaps Quest can turn around and sell their ~40% which will end up in Quest's bank to benefit the shareholders. At least this is what I am hoping for. 

Any other thoughts on this deal?    

https://questpharmatech.com/wp-content/uploads/2020/04/NR22042020.pdf  

jmo
G1945V
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities